The prevalence of mental disorders among homeless people in high-income countries: An updated systematic review and meta-regression analysis.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
02
02
2021
accepted:
02
08
2021
revised:
07
09
2021
pubmed:
24
8
2021
medline:
11
11
2021
entrez:
23
8
2021
Statut:
epublish
Résumé
Homelessness continues to be a pressing public health concern in many countries, and mental disorders in homeless persons contribute to their high rates of morbidity and mortality. Many primary studies have estimated prevalence rates for mental disorders in homeless individuals. We conducted a systematic review and meta-analysis of studies on the prevalence of any mental disorder and major psychiatric diagnoses in clearly defined homeless populations in any high-income country. We systematically searched for observational studies that estimated prevalence rates of mental disorders in samples of homeless individuals, using Medline, Embase, PsycInfo, and Google Scholar. We updated a previous systematic review and meta-analysis conducted in 2007, and searched until 1 April 2021. Studies were included if they sampled exclusively homeless persons, diagnosed mental disorders by standardized criteria using validated methods, provided point or up to 12-month prevalence rates, and were conducted in high-income countries. We identified 39 publications with a total of 8,049 participants. Study quality was assessed using the JBI critical appraisal tool for prevalence studies and a risk of bias tool. Random effects meta-analyses of prevalence rates were conducted, and heterogeneity was assessed by meta-regression analyses. The mean prevalence of any current mental disorder was estimated at 76.2% (95% CI 64.0% to 86.6%). The most common diagnostic categories were alcohol use disorders, at 36.7% (95% CI 27.7% to 46.2%), and drug use disorders, at 21.7% (95% CI 13.1% to 31.7%), followed by schizophrenia spectrum disorders (12.4% [95% CI 9.5% to 15.7%]) and major depression (12.6% [95% CI 8.0% to 18.2%]). We found substantial heterogeneity in prevalence rates between studies, which was partially explained by sampling method, study location, and the sex distribution of participants. Limitations included lack of information on certain subpopulations (e.g., women and immigrants) and unmet healthcare needs. Public health and policy interventions to improve the health of homeless persons should consider the pattern and extent of psychiatric morbidity. Our findings suggest that the burden of psychiatric morbidity in homeless persons is substantial, and should lead to regular reviews of how healthcare services assess, treat, and follow up homeless people. The high burden of substance use disorders and schizophrenia spectrum disorders need particular attention in service development. This systematic review and meta-analysis has been registered with PROSPERO (CRD42018085216). PROSPERO CRD42018085216.
Sections du résumé
BACKGROUND
Homelessness continues to be a pressing public health concern in many countries, and mental disorders in homeless persons contribute to their high rates of morbidity and mortality. Many primary studies have estimated prevalence rates for mental disorders in homeless individuals. We conducted a systematic review and meta-analysis of studies on the prevalence of any mental disorder and major psychiatric diagnoses in clearly defined homeless populations in any high-income country.
METHODS AND FINDINGS
We systematically searched for observational studies that estimated prevalence rates of mental disorders in samples of homeless individuals, using Medline, Embase, PsycInfo, and Google Scholar. We updated a previous systematic review and meta-analysis conducted in 2007, and searched until 1 April 2021. Studies were included if they sampled exclusively homeless persons, diagnosed mental disorders by standardized criteria using validated methods, provided point or up to 12-month prevalence rates, and were conducted in high-income countries. We identified 39 publications with a total of 8,049 participants. Study quality was assessed using the JBI critical appraisal tool for prevalence studies and a risk of bias tool. Random effects meta-analyses of prevalence rates were conducted, and heterogeneity was assessed by meta-regression analyses. The mean prevalence of any current mental disorder was estimated at 76.2% (95% CI 64.0% to 86.6%). The most common diagnostic categories were alcohol use disorders, at 36.7% (95% CI 27.7% to 46.2%), and drug use disorders, at 21.7% (95% CI 13.1% to 31.7%), followed by schizophrenia spectrum disorders (12.4% [95% CI 9.5% to 15.7%]) and major depression (12.6% [95% CI 8.0% to 18.2%]). We found substantial heterogeneity in prevalence rates between studies, which was partially explained by sampling method, study location, and the sex distribution of participants. Limitations included lack of information on certain subpopulations (e.g., women and immigrants) and unmet healthcare needs.
CONCLUSIONS
Public health and policy interventions to improve the health of homeless persons should consider the pattern and extent of psychiatric morbidity. Our findings suggest that the burden of psychiatric morbidity in homeless persons is substantial, and should lead to regular reviews of how healthcare services assess, treat, and follow up homeless people. The high burden of substance use disorders and schizophrenia spectrum disorders need particular attention in service development. This systematic review and meta-analysis has been registered with PROSPERO (CRD42018085216).
TRIAL REGISTRATION
PROSPERO CRD42018085216.
Identifiants
pubmed: 34424908
doi: 10.1371/journal.pmed.1003750
pii: PMEDICINE-D-21-00563
pmc: PMC8423293
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003750Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202836/Z/16/Z
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Arch Gen Psychiatry. 1989 Sep;46(9):845-50
pubmed: 2774850
J R Stat Soc Ser A Stat Soc. 2009 Jan;172(1):137-159
pubmed: 19381330
BMJ Open. 2019 Dec 29;9(12):e032576
pubmed: 31888930
BMJ. 1994 Mar 26;308(6932):816-9
pubmed: 8167488
J Pers Disord. 2008 Dec;22(6):573-88
pubmed: 19072678
Arch Gen Psychiatry. 1985 Feb;42(2):181-6
pubmed: 3883940
Alcohol Alcohol. 2010 Jul-Aug;45(4):387-94
pubmed: 20554697
Res Synth Methods. 2016 Mar;7(1):55-79
pubmed: 26332144
Soc Sci Med. 2008 Nov;67(9):1475-9
pubmed: 18703266
J Clin Psychiatry. 1993 Mar;54(3):82-7
pubmed: 8468313
Am J Psychiatry. 1984 Dec;141(12):1546-50
pubmed: 6209990
Addiction. 2013 Oct;108(10):1722-33
pubmed: 23844822
BMC Health Serv Res. 2014 Sep 07;14:376
pubmed: 25196184
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Am J Community Psychol. 2016 Sep;58(1-2):123-35
pubmed: 27473922
Br J Gen Pract. 2019 Aug;69(685):e515-e525
pubmed: 31262848
Scott Med J. 1997 Dec;42(6):173-7
pubmed: 9507596
Soc Psychiatry Psychiatr Epidemiol. 2010 Nov;45(11):1055-62
pubmed: 19816646
Psychiatr Prax. 2017 Sep;44(6):339-347
pubmed: 27627115
J Clin Epidemiol. 2012 Sep;65(9):934-9
pubmed: 22742910
Soc Psychiatry Psychiatr Epidemiol. 2015 Aug;50(8):1285-91
pubmed: 25708192
Int J Environ Res Public Health. 2018 Jan 31;15(2):
pubmed: 29385053
Nihon Koshu Eisei Zasshi. 2011 May;58(5):331-9
pubmed: 21905609
BMC Med Res Methodol. 2017 Dec 6;17(1):162
pubmed: 29207961
Psychiatr Serv. 1997 Apr;48(4):504-9
pubmed: 9090734
Nervenarzt. 2020 Oct 14;:
pubmed: 33052424
J Nerv Ment Dis. 1998 Jul;186(7):393-400
pubmed: 9680039
Br J Psychiatry. 1996 Jan;168(1):82-6
pubmed: 8770434
Sex Transm Dis. 2018 Jul;45(7):494-504
pubmed: 29465661
Psychiatr Serv. 2014 Jun 1;65(6):739-50
pubmed: 24535245
BMC Psychiatry. 2019 Nov 27;19(1):370
pubmed: 31775786
Acta Psychiatr Scand. 2001 Feb;103(2):94-104
pubmed: 11167311
PLoS One. 2015 Sep 17;10(9):e0138052
pubmed: 26378447
JAMA. 2015 Mar 3;313(9):905-15
pubmed: 25734732
Am J Public Health. 1986 May;76(5):519-24
pubmed: 3963280
Int J Methods Psychiatr Res. 2011 Mar;20(1):40-9
pubmed: 21499542
PLoS Med. 2008 Dec 2;5(12):e225
pubmed: 19053169
N Engl J Med. 2012 Oct 4;367(14):1355-60
pubmed: 23034025
J Nerv Ment Dis. 2000 Mar;188(3):135-40
pubmed: 10749277
Nervenarzt. 1996 Nov;67(11):930-4
pubmed: 9064553
Arch Gen Psychiatry. 1988 Dec;45(12):1085-92
pubmed: 2461690
Arch Gen Psychiatry. 2003 Sep;60(9):940-51
pubmed: 12963676
Soc Work Health Care. 2013;52(5):449-66
pubmed: 23701578
Eur Arch Psychiatry Clin Neurosci. 1997;247(3):162-72
pubmed: 9224909
JAMA Psychiatry. 2018 Apr 1;75(4):336-346
pubmed: 29450462
Int J Soc Psychiatry. 2014 Sep;60(6):544-53
pubmed: 24084471
Dtsch Arztebl Int. 2017 Oct 06;114(40):665-672
pubmed: 29070426
Psychiatr Q. 2019 Dec;90(4):829-842
pubmed: 31463733
J Health Care Poor Underserved. 2013 Feb;24(1):97-105
pubmed: 23377721
J Nerv Ment Dis. 2015 Feb;203(2):126-31
pubmed: 25594792
Soc Psychiatry Psychiatr Epidemiol. 2005 May;40(5):382-90
pubmed: 15902408
Am J Public Health. 2015 Feb;105(2):e46-60
pubmed: 25521899
Int Rev Psychiatry. 2003 Feb-May;15(1-2):141-3
pubmed: 12745322
JAMA Intern Med. 2013 Feb 11;173(3):189-95
pubmed: 23318302
Ned Tijdschr Geneeskd. 2001 Jun 16;145(24):1161-6
pubmed: 11433665
Gen Hosp Psychiatry. 2005 Nov-Dec;27(6):418-25
pubmed: 16271656
Ir J Psychol Med. 2019 Mar;36(1):19-22
pubmed: 30931876
Hum Genet. 2012 Jun;131(6):779-89
pubmed: 22543841
Aust N Z J Psychiatry. 1985 Sep;19(3):233-8
pubmed: 3866566
CMAJ. 2020 Jun 29;192(26):E716-E719
pubmed: 32601252
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Soc Psychiatry Psychiatr Epidemiol. 2013 Aug;48(8):1225-34
pubmed: 23508368
Addiction. 2002 Dec;97(12):1593-600
pubmed: 12472643
BMC Public Health. 2012 Dec 08;12:1059
pubmed: 23216886
Lancet Infect Dis. 2012 Nov;12(11):859-70
pubmed: 22914343
Lancet. 2011 Jun 25;377(9784):2205-14
pubmed: 21676456
Psychiatr Prax. 2021 Apr;48(3):156-160
pubmed: 33232977
Lancet. 1987 Mar 7;1(8532):553-4
pubmed: 2881093
BMJ. 2011 Feb 10;342:d549
pubmed: 21310794
Soc Psychiatry Psychiatr Epidemiol. 1999 Nov;34(11):580-7
pubmed: 10651176
Int J Soc Psychiatry. 2020 Sep;66(6):528-541
pubmed: 32460590
Eur Neuropsychopharmacol. 2005 Aug;15(4):357-76
pubmed: 15961293
Am J Psychiatry. 1989 Sep;146(9):1179-84
pubmed: 2764176
Soc Psychiatry Psychiatr Epidemiol. 2001 Apr;36(4):207-16
pubmed: 11518035
Front Psychiatry. 2020 Jun 03;11:508
pubmed: 32581882
Am J Public Health. 2005 Oct;95(10):1753-9
pubmed: 16131638
Psychiatr Prax. 2004 Jul;31(5):228-35
pubmed: 15243872
J Epidemiol Community Health. 2013 Nov 1;67(11):974-8
pubmed: 23963506
Psychiatr Prax. 2004 Jul;31(5):236-40
pubmed: 15243873
Ment Health Serv Res. 2000 Sep;2(3):155-64
pubmed: 11256724
Soc Psychiatry Psychiatr Epidemiol. 2013 Aug;48(8):1235-43
pubmed: 23299926
J Public Health (Oxf). 2018 Mar 1;40(1):65-74
pubmed: 28335013
J Am Acad Child Adolesc Psychiatry. 2015 Feb;54(2):86-96.e2
pubmed: 25617249
Int Rev Psychiatry. 2003 Feb-May;15(1-2):134-40
pubmed: 12745321
Lancet. 2014 Oct 25;384(9953):1529-40
pubmed: 25390578
Psychol Addict Behav. 2008 Sep;22(3):410-6
pubmed: 18778134
PLoS One. 2013 Oct 02;8(10):e73979
pubmed: 24098329
Compr Psychiatry. 1979 Sep-Oct;20(5):454-62
pubmed: 90581
PLoS Med. 2020 Jul 6;17(7):e1003172
pubmed: 32628679
BMC Health Serv Res. 2014 Sep 18;14:404
pubmed: 25230990
Lancet. 2018 Jan 20;391(10117):241-250
pubmed: 29137869
Health Trends. 1989 Aug;21(3):70-1
pubmed: 10295816